Bristol-Myers Squibb Aktie News

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of h...

Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Boerner - CEO & Chairman Adam Lenkowsky - Executive VP & Chief Commercialization Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst All right. Thanks. I think ...

A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.

Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hodgkin lymphoma called Breyanzi reached $344 million in Q2 2025, increasing by more than 100% year-on-year. Moreover, Bristol-Myers may expand its label on December 5, 2025, and become the first CAR ...

Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy declines and positioning BMY for a turnaround. Valuation is compelling: BMY trades at a deep discount to peers, with limited downside and strong profitability metrics.

These blue-chip dividend stocks have dependable underlying businesses. You get an equally dependable dividend yield of over 5%.

Visa has demonstrated why it remains the market leader in the global payment processor market, thanks to its robust, profitable growth cadence.

Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in its legacy segment. Notably, BMY's robust profitability and a sector-leading dividend yield help to secure buy-in from income investors with the patience to ride out the near-term turbulence.